Pyxis Oncology (PYXS) Change in Account Payables (2020 - 2025)
Pyxis Oncology (PYXS) posted quarterly Change in Account Payables of $1.1 million for Q4 2025, up 11390.0% year-over-year from N/an in Q4 2024, and up 228.2% quarter-over-quarter from $344000.0 in Q3 2025.
Pyxis Oncology (PYXS) Change in Account Payables (2020 - 2025) Analysis & Trends
Pyxis Oncology (PYXS) has reported Change in Account Payables for 6 consecutive years, with $1.1 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Change in Account Payables rose 11390.0% year-over-year to $1.1 million; the TTM figure through Dec 2025 stood at $6.0 million (up 402.17% YoY), while the FY2025 annual figure was $6.0 million, up 402.17% from the prior year.
- Change in Account Payables improved to $1.1 million in Q4 2025 per PYXS's latest filing, from $344000.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $6.6 million in Q2 2025 and bottomed at -$9.9 million in Q1 2022.
- Historically, Change in Account Payables has averaged $1700.0 across 5 years, with a median of -$228500.0 in 2021.
- Annual changes were most pronounced in 2022 — Change in Account Payables tumbled 2113.87% — and 2025, when it jumped 11390.0%.
- Pyxis Oncology's Change in Account Payables stood at $4.0 million in 2021, then sank by 146.74% to -$1.9 million in 2022, then surged by 118.57% to $350000.0 in 2023, then tumbled by 102.86% to -$10000.0 in 2024, then surged by 11390.0% to $1.1 million in 2025.
- Business Quant data shows PYXS's Change in Account Payables at $1.1 million in Q4 2025, $344000.0 in Q3 2025, and $6.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Pyxis Oncology | 198.37 Mn | 165.38 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.13 Mn |
| Dec 31, 2025 | 1.13 Mn |
| Sep 30, 2025 | 344,000.00 |
| Sep 30, 2025 | 344,000.00 |
| Jun 30, 2025 | 6.57 Mn |
| Jun 30, 2025 | 6.57 Mn |
| Mar 31, 2025 | -2.01 Mn |
| Mar 31, 2025 | -2.01 Mn |
| Dec 31, 2024 | -10,000.00 |
| Dec 31, 2024 | -10,000.00 |
| Sep 30, 2024 | -602,000.00 |
| Sep 30, 2024 | -602,000.00 |
| Jun 30, 2024 | 3.18 Mn |
| Jun 30, 2024 | 3.18 Mn |
| Mar 31, 2024 | -1.37 Mn |
| Mar 31, 2024 | -1.37 Mn |
| Dec 31, 2023 | 350,000.00 |
| Dec 31, 2023 | 350,000.00 |
| Sep 30, 2023 | -1.54 Mn |
| Sep 30, 2023 | -1.54 Mn |